Immediate Impact
53 standout
Citing Papers
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
2025 Standout
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
2024 Standout
Works of John T. Huggins being referenced
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
2018
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| John T. Huggins | 1529 | 352 | 532 | 436 | 61 | 1.9k | |
| E Neville | 1875 | 231 | 629 | 1306 | 44 | 2.8k | |
| Sow-Hsong Kuo | 1114 | 343 | 337 | 314 | 66 | 2.1k | |
| Stephen I. Schabel | 771 | 139 | 578 | 140 | 68 | 1.5k | |
| Oksana A. Shlobin | 2496 | 101 | 588 | 720 | 108 | 3.0k | |
| Steven D. Shapiro | 1044 | 107 | 199 | 390 | 38 | 2.3k | |
| Carlos A. Jiménez | 1288 | 91 | 396 | 139 | 82 | 1.7k | |
| John Robert | 1406 | 148 | 870 | 109 | 54 | 2.5k | |
| Praveen N. Mathur | 1589 | 121 | 751 | 197 | 79 | 1.9k | |
| Jörg Fehr | 333 | 76 | 432 | 258 | 46 | 2.6k | |
| R. Egbring | 643 | 171 | 201 | 131 | 65 | 1.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...